Biogen Inc. (Nasdaq: BIIB) announces the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen. The acquisition adds two best-in-class commercialized products, EMPAVELI® and SYFOVRE®, significantly bolstering Biogen’s near-term growth outlook and accelerating the Company’s expansion into nephrology. Together, the products recorded $689 million in net product revenue in 2025.
Read the full article: Biogen Completes Acquisition of Apellis Pharmaceuticals //
Source: https://www.globenewswire.com/news-release/2026/05/14/3294955/0/en/biogen-completes-acquisition-of-apellis-pharmaceuticals.html